Lombard Medical, Inc. is a public company focused principally on the worldwide endovascular repair (EVAR) market, estimated to be approximately $1.6 billion in 2015, with the U.S. market estimated at approximately $680 million. Lombard Medical’s lead product, Aorfix™, is the only stent-graft approved by the United States Food and Drug Administration (FDA) for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees